Correlation Between Sarepta Therapeutics and Spyre Therapeutics
Can any of the company-specific risk be diversified away by investing in both Sarepta Therapeutics and Spyre Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sarepta Therapeutics and Spyre Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sarepta Therapeutics and Spyre Therapeutics, you can compare the effects of market volatilities on Sarepta Therapeutics and Spyre Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sarepta Therapeutics with a short position of Spyre Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sarepta Therapeutics and Spyre Therapeutics.
Diversification Opportunities for Sarepta Therapeutics and Spyre Therapeutics
0.09 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Sarepta and Spyre is 0.09. Overlapping area represents the amount of risk that can be diversified away by holding Sarepta Therapeutics and Spyre Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spyre Therapeutics and Sarepta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sarepta Therapeutics are associated (or correlated) with Spyre Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spyre Therapeutics has no effect on the direction of Sarepta Therapeutics i.e., Sarepta Therapeutics and Spyre Therapeutics go up and down completely randomly.
Pair Corralation between Sarepta Therapeutics and Spyre Therapeutics
Given the investment horizon of 90 days Sarepta Therapeutics is expected to generate 1.0 times more return on investment than Spyre Therapeutics. However, Sarepta Therapeutics is 1.0 times more volatile than Spyre Therapeutics. It trades about 0.14 of its potential returns per unit of risk. Spyre Therapeutics is currently generating about -0.37 per unit of risk. If you would invest 11,248 in Sarepta Therapeutics on September 14, 2024 and sell it today you would earn a total of 1,199 from holding Sarepta Therapeutics or generate 10.66% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Sarepta Therapeutics vs. Spyre Therapeutics
Performance |
| Timeline |
| Sarepta Therapeutics |
| Spyre Therapeutics |
Sarepta Therapeutics and Spyre Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Sarepta Therapeutics and Spyre Therapeutics
The main advantage of trading using opposite Sarepta Therapeutics and Spyre Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sarepta Therapeutics position performs unexpectedly, Spyre Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spyre Therapeutics will offset losses from the drop in Spyre Therapeutics' long position.| Sarepta Therapeutics vs. Puma Biotechnology | Sarepta Therapeutics vs. Iovance Biotherapeutics | Sarepta Therapeutics vs. Day One Biopharmaceuticals | Sarepta Therapeutics vs. Inozyme Pharma |
| Spyre Therapeutics vs. Puma Biotechnology | Spyre Therapeutics vs. Iovance Biotherapeutics | Spyre Therapeutics vs. Day One Biopharmaceuticals | Spyre Therapeutics vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Complementary Tools
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |